Moderna Ebola Vaccine Cleared to Advance to Phase 2/3 Trial in Congo; Shares Up 8.2%
MRNA has more than doubled off its 52-week low of $22.28 on light trading volume (0.3× avg).
Summary
Moderna's mRNA-1469 Ebola vaccine was recommended to move into a Phase 2/3 trial in Congo, pending regulatory approval, targeting the Bundibugyo ebolavirus amid an ongoing outbreak there. The recommendation follows an October review by a WHO advisory group that weighed Phase 1 interim data showing the shot was generally well tolerated with encouraging signs of protective response. CEPI, which has committed up to $58.5 million for preclinical and Phase 1 work, is putting separate funding into the Phase 2/3 study. Shares rose 8.2% to $247.23 Wednesday, extending a year in which the stock has climbed more than eightfold on the back of the melanoma vaccine data. The trial is a modest commercial opportunity on its own — the real driver remains the intismeran cancer program — but it reinforces the mRNA platform narrative that has powered the stock to near its 52-week high.
At the time of this announcement, MRNA was trading at $247.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $98.7B. The 52-week trading range was $22.28 to $254.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.